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Abstract
Background: The cytosolic retinoic acid-inducible gene I (RIG-I) is a pattern recognition receptor that senses HCV
double-stranded RNA and triggers type I interferon pathways. The clone Huh7.5 of human hepatoma Huh7 cells
contains a mutation in RIG-I that is believed to be responsible for the improved replication of HCV in these cells
relative to the parental strain. We hypothesized that, in addition to RIG-I, other determinant(s) outside the RIG-I
coding sequence are involved in limiting HCV replication in cell culture. To test our hypothesis, we analyzed Huh7
cell clones that support the efficient replication of HCV and analyzed the RIG-I gene.
Results: One clone, termed Huh7D, was more permissive for HCV replication and more efficient for HCV-neomycin
and HCV-hygromycin based replicon colony formation than parental Huh7 cells. Nucleotide sequence analysis of
the RIG-I mRNA coding region from Huh7D cells showed no mutations relative to Huh7 parental cells.
Conclusions: We derived a new Huh7 cell line, Huh7D, which is more permissive for HCV replication than parental
Huh7 cells. The higher permissiveness of Huh7D cells is not due to mutations in the RIG-I protein, indicating that
cellular determinants other than the RIG-I amino-acid sequence are responsible for controlling HCV replication. In
addition, we have selected Huh7 cells resistant to hygromycin via newly generated HCV-replicons carrying the
hygromycin resistant gene. Further studies on Huh7D cells will allow the identification of cellular factors that
increased the susceptibility to HCV infection, which could be targeted for anti-HCV therapies.
Background
Hepatitis C virus (HCV) infects nearly 200 million peo-
ple worldwide [1]. HCV infection causes chronic liver
disease, cirrhosis, and is associated with hepatocellular
carcinoma [2]. It is estimated that only 15-40% of
infected people resolve acute HCV infection [3], sug-
gesting that host factors are capable of controlling HCV
replication in some individuals. However, the host deter-
minants responsible for controlling HCV replication are
not well understood. The ability to grow HCV in vitro is
important for understanding both virologic and immu-
nologic aspects of HCV infections. It has been shown
that the JFH1 and the chimeric J6/JFH1 isolate of the 2a
genotype of HCV replicate efficiently in Huh7 cells [4,5]
and in the highly permissive Huh7.5 and Huh7.5.1 cells
derived from the human hepatoma cell line Huh7 [6-9].
Later, production of infectious genotype 1a and 1b
viruses [10] was demonstrated in Huh7.5 cells. Further
studies showed that the increased permissiveness of
Huh7.5 cells results from a mutation (Thr-55-Iso) in the
RIG-I gene (retinoic acid-inducible gene I, a DExD/H
domain containing RNA helicase, reviewed in [11])
which impairs interferon signaling [12]. In this study,
using a technique similar to that used to generate the
Huh7.5 cell line, we derived another Huh7 cell line
highly permissive for HCV replication that we termed
Huh7D. We compared the replication of the genotype
2 aJ 6 / J F H 1s t r a i no fH C Va n dt h eg e n o t y p e1 bb a s e d
HCV replicons in Huh7D cells with replication in Huh7
and Huh7.5 cells. We found that while HCV replicated
better in Huh7D cells relative to Huh7 cells, no muta-
tions were found in the RIG-I coding region from
Huh7D cells, indicating that cellular determinants
located outside the RIG-I amino-acid coding sequence
are responsible for the higher permissiveness of Huh7D
cells for HCV replication.
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Huh7D cells are more susceptible to HCV replicons than
parental Huh7 cells
To compare the susceptibility of cells to HCV replicons,
Huh7, Huh7D, and Huh7.5 cells were transfected with
HCV-neo-Replicon and selected with 250 μg/ml of G-
418. An increased number of neomycin-resistant colo-
nies were observed in Huh7D cells (and control Huh7.5
cells) relative to Huh7 cells (figure 1), irrespective of the
amount of transfected RNA. No surviving colonies were
observed in replication-defective HCV-neo-Replicon,
unrelated RNA (transcribed from pTRI-Xef plasmid
from AMBION kit), or no RNA transfected cells (figure
1 and additional file 1). In order to quantify the effi-
ciency of colony formation (ECF), we repeated the
experiment using lower amounts of replicon, and
obtained ECF of 526, 10,500, and 2631 colonies per μg
of transfected RNA for Huh7, Huh7D, and Huh7.5 cells
respectively (additional file 1). Wild type HCV-neo repli-
cons obtained by in vitro transcription of Sca1 cut plas-
mid pFK i389neoNS3-3’/WT and other less adapted
replicons (Feigelstock et al, unpublished) also yielded
more colonies in Huh7D cells relative to Huh7 cells.
These results show Huh7D cells have an increased capa-
city to survive G-418 via HCV-neo-Replicon than paren-
tal Huh7 cells, suggesting that the HCV replicon
replicates better in Huh7D cells relative to Huh7 cells.
The increased susceptibility of Huh7D cells to HCV-
replicons is independent of the selectable marker coded
by the HCV-replicon
To determine whether the selectable marker contained
in the HCV-replicon had an effect in the susceptibility
of the Huh7 cell clones, we transfected Huh7, Huh7D,
and Huh7.5 cells with approximately 100 ng of the indi-
cated HCV-hyg-Replicons and selected cells with 65 μg/
ml hygromycin B. At 40 days post-transfection, more
hygromycin B resistant colonies were observed in
Huh7D and Huh7.5 cells than in Huh7 cells whereas
mock-transfected cells did not survive the antibiotic
s e l e c t i o n( f i g u r e2 a ) .A ss h o w ni nf i g u r e2 a ,w ew e r e
able to select Huh7 colonies resistant to hygromycin B;
however, those initially resistant colonies didn’ts u r v i v e
longer (more than 60 days) treatment with hygromycin
B. Replication of HCV-hyg-Replicon in Huh7D and
Huh7.5 cells was confirmed by immunfluorscence analy-
sis (figure 2b). Transfection with HCV-hyg-Replicons
yielded a low number of surviving colonies and, given
the extended time required for hygromycin to kill Huh7
cells, we needed to make a cell passage resulting in the
loss of our ability to accurately quantify the differences
in transduction efficiencies. These data indicate that the
selectable marker has no effect in the higher susceptibil-
ity of the Huh7 clones to HCV replicons.
Huh7D cells are more susceptible to HCV infection than
Huh7 parental cells
We next wanted to determine whether Huh7D cells
were more susceptible to HCV replication than parental
Huh7 cells when using the J6/JFH1 infectious clone. To
do so, we infected Huh7, Huh7D, and Huh7.5 cells with
HCV-J6/JFH1 at an m.o.i. of 0.01 and analyzed virus
growth at 0, 1, 3, 5, 7, 10, and 15 dpi using an IF end-
point dilution titration assay and by IF on infected cells.
HCV J6/JFH1 grew faster in Huh7D and Hu7.5 cells
relative to Huh7 cells (figure 3a), which is consistent
with our results showing that the Huh7D and Huh7.5
cells were more susceptible to HCV replicons than the
parental Huh7 cells. Cells passed to 96 well plates were
stained with anti-HCV antibodies at 3, 5, and 10 dpi,
and HCV antigen was detected by IF analysis (figure
3b). In agreement with the titration data, Huh7D and
Huh7.5 cells showed an increase in the percentage of
infected cells relative to Huh7 cells. These results show
that J6/JFH1 virus grew better in Huh7D cells and in
Huh7.5 cells than in Huh7 cells. In order to discard the
possibility that the J6/JFH1 virus grew better in Huh7D
cells relative to Huh7 and Huh7.5 cells because it was
produced in Huh7D cells (and therefore may have
acquired Huh7D adaptive mutations), we sequenced the
full length genome of the J6/JFH1 virus we used to
inoculate the cells. We found no differences in the
nucleotide sequence with respect to the J6/JFH1
sequence present in the plasmid, except in three posi-
tions that showed a mixture of two nucleotides
(T2667T/C; A7150G/A; and T7667T/A). In addition, we
repeated the experiment shown in figure 3 but using a
J6/JFH1 virus that had been grown only in Huh7.5 cells
and therefore there was no chance that the virus had
adapted to the Huh7D cells prior to studying the repli-
cation of the virus in those cells. Again we saw higher
titers in Huh7D relative to Huh7 cells (2 logs). This
result suggest that the observed higher susceptibility of
Huh7D cells to J6/JFH1 infection is not due to adapta-
tion of the virus to Huh7D cells. Furthermore, JFH1
virus (also not passaged in Huh 7D cells) also grew bet-
ter in Huh7D and Huh7.5 cells relative to Huh7 cells
(not shown).
There are no amino-acid substitutions in the RIG-I coding
region from Huh7D cells
In order to determine if the increased susceptibility of
Huh7D cells to HCV replication was due to mutations
in RIG-I as observed in Huh7.5 cells [12], we sequenced
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Huh7D, and Huh7.5 cells by RT-PCR. The RIG-I coding
region sequence was identical in Huh7D and parental
Huh7 cells while the expected ACA to ATA (Thr-55-
Iso) substitution was found in Huh7.5 cells (additional
file 2).
Discussion
In this study we derived Huh7D cells, a single cell clone
of replicon-cured Huh7 cells. We show that as the pre-
viously reported Huh7.5 cells, Huh7D cells are more
permissive to HCV replication than parental Huh7 cells.
Huh7D cells were similarly permissive to HCV replicon
(neo and hyg) replication as Huh7.5 cells, and were at
least as permissive to HCV J6/JFH1 infection as Huh7.5
cells. Sequencing of the coding region of RIG-I mRNA
from Huh7D cells, as opposed to the RIG-I coding
region from Huh7.5 cells, showed no mutations when
compared to the RIG-I coding region from parental
Huh7 cells. This indicates that mutations in RIG-I cod-
ing region are not responsible for the higher permissive-
ness of Huh7D cells to HCV replication. This is in
agreement with recent observations indicating that an
intact RIG-I signaling pathway does not necessarily limit
HCV replication in Huh-7 cells [13].
At this time we have not identified the factor/s
responsible for the higher permissiveness of Huh7D
cells. Other than RIG-I cellular factors affecting HCV
Huh7
Mock             60 ng  120 ng
Huh7D
Huh7.5 
Figure 1 Transfection of HCV-neo-replicon into Huh7, Huh7D, and Huh7.5 cells. Coomassie staining of Huh7, Huh7D, and Huh7.5 cells that
were transfected with the indicated amounts of HCV-neo replicon and selected for 13 days with G-418 at a concentration of 250 μg/ml.
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receptor 3 (TLR3) in Huh7 and Huh7.5 cells senses
HCV infection independently of RIG-I, and triggers an
antiviral state [14]. Class III Phosphatidylinositol 4-
Kinase alpha and beta were recently identified as regula-
tors of hepatitis C virus replication in Huh7 cells [15]. A
screening using siRNA identified host genes that modu-
late HCV replication, including host genes related to the
RNAi pathway [16], transcription factors, transporter
proteins, and others [17].
In order to obtain a Huh7 cell line with even higher
permissiveness for HCV replication, we selected double
cured Huh7 cells (cells selected with HCV-neo replicon,
cured, selected with HCV-hyg replicon, and cured again,
or cells selected twice with HCV-neo replicons), but we
couldn’t obtain Huh7 cells with higher permissiveness
for HCV replicon replication or HCV infection (not
shown). The failure to obtain cells that are more per-
missive to HCV replication by successive curing of
transfected cells suggests that cellular mechanisms
involved in HCV replication are difficult to alter. It is
also possible that interferon signaling is the major cellu-
lar mechanism for controlling HCV replication (and/or
the easiest to alter), and once this pathway is altered,
few other (alterable) pathways are left to facilitate HCV
replication.
We have shown that Huh7D cells are more permissive
than Huh7 cells not only for a replicon with the neo
selectable marker, but also for an HCV replicon which
expresses the hygromycin resistance gene. We were able
to select Huh7D (and Huh7.5) but not Huh7 cells resis-
tant to hygromycin B after HCV-hyg replicon transfec-
t i o n .A l t h o u g hw ew e r ea b l et oi n i t i a l l ys e l e c tH u h 7
cells resistant to hygromycin B, treatment with the anti-
biotic for periods longer than 60 days induced the
extinction of the Huh7 colonies. This observation sug-
gest that replication of HCV-hyg-rep in Huh7 cells is
limited, but the lesser susceptibility of Huh7 cells to
Mock HCV-hyg-Rep
cl 2 (Spe1 cut)
HCV-hyg-Rep
cl 3 (Spe1 cut)
HCV-hyg-Rep 
cl 1 (Sca1 cut)
HCV-hyg-Rep 
cl 8 (Sca1 cut)
Huh7 - - + ++ -
Huh7D - +++ +++++ ++++++ +++
Huh7.5 - - +++++ ++++++ ++++
Mock transfected HCV-hyg-rep transf. HCV J6/JFH1 infected
A
B
Huh7D
Huh7.5
Figure 2 Transfection of HCV-hyg-replicons into Huh7, Huh7D, and Huh7.5 cells and selection with hygromycin B at a concentration
of 65 μg/ml. A. Relative quantification of surviving colonies. B. Detection of HCV antigens in surviving Huh7D and Huh7.5 cells at 37 days post
transfection by immunfluorscence.
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fact, while mock transfected Huh7 cells survive 250 μg/
ml Neomycin for about 2 weeks, mock transfected
Huh7 cells survive 65 μg/ml hygromycin for about 30
days. Obtaining resistance to hygromycin B was more
difficult and less efficient than obtaining resistance to
neomycin. We don’t know the reason underlying this
observation, which together with the fact that resistance
of Huh7 cells to hygromycin B via HCV-hyg replicons
was not widely reported, suggest the presence of intrin-
sic barriers for Huh7 cells to survive hygromycin B
using HCV-hyg replicons.
1.0E+00
1.0E+01
1.0E+02
1.0E+03
1.0E+04
1.0E+05
1.0E+06
1.0E+07
0 5 10 15 20
Huh7
Huh7D
Huh7.5
mock
Huh7
Huh7D
3 day 5 day
Huh7.5
10 day
A
B
Figure 3 A. Growth of HCV2a J6/JFH1 in Huh7, Huh7D, and Huh7.5 cells. The indicated cells were mock infected or infected the J6/JFH1
strain of HCV at an m.o.i. of 0.01. After 6 hours, cells were washed with growth medium three times and passed to 12 well plates. Cells were
collected at the indicated time points and frozen at -70°C. Virus was tittered as described in the text. Ffu, focus forming units. Error bars
represent the standard error. B. Growth of HCV2a J6/JFH1 in Huh7, Huh7D, and Huh7.5 cells assessed by IF. The indicated cells were mock
infected or infected the J6/JFH1 strain of HCV at an m.o.i. of 0.01. After 6 hours, cells were washed with growth medium for three times and
passed to 96 well plates. HCV antigen was detected at the indicated time points by immunfluorscence.
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In this study we derived a new Huh7 cell line (Huh7D)
which is more permissive for HCV replication than par-
ental Huh7 cells. The permissiveness of Huh7D cells is
not due to mutations in the RIG-I protein, as reported
for the widely used Huh7.5 cells. More experiments are
needed to elucidate if the cellular determinant/s respon-
sible for the higher permissiveness of Huh7D cells are
related to the interferon or other cellular pathways.
Methods
Cells
Huh7 and Huh7.5 cells were a gift from Jake Liang.
Huh7, Huh7D, and Huh7.5 cells were grown in DMEM
(Gibco) supplemented with 10% bovine calf serum
(Atlanta Biologicals), L-glutamine (Gibco), penicillin and
streptomycin (Gibco).
Viruses
The JFH1 virus was a gift from Takaji Wakita. J6/JFH1
virus was obtained by transfection of Huh7D cells (see
below) with in vitro transcribed HCV J6/JFH1 RNA.
HCV J6/JFH1 RNA was obtained from plasmid pFL- J6/
JFH1 (a gift from Charles Rice) that was cut with Xba1
and transcribed with T7 RNA polymerase (T7 Mega-
script AMBION).
Generation of HCV replicon containing the neomycin
resistance gene ("HCV-neo-Rep”)
HCV-neo-Replicon and replication-defective HCV repli-
con were obtained as previously described [18]. Briefly,
plasmid pFK i389neoNS3-3’/NK5.1 coding for a highly
permissive HCV-neo replicon harboring several replica-
tion enhancing mutations [19] and plasmid pFK
i389neoNS3-3’/delta5B [18] (kindly provided by Ralph
Bartenschlager) were cut with restriction enzyme Sca1,
and in vitro transcribed using T7 Megascript kit
(AMBION).
Generation of HCV replicon containing the hygromycin
resistance gene ("HCV-hyg-Rep”)
To obtain HCV replicons carrying the hygromycin resis-
tance gene ("HCV-hyg-Rep”) we replaced the neomycin
resistance gene with the hygromycin resistance gene in
plasmid pFK i389neoNS3-3’/NK5.1 using restriction
enzymes Asc1 and Pme1. Hygromycin resistance gene
was obtained by PCR using plasmid pIREShyg (Clon-
tech) as template and sense oligo AAC-
TAAAGGCGCGCCATGGATAGATCCGGAAAGCCT-
GAACTCAC (carrying the Asc1 restriction site) and
anti-sense oligo AGTTATGGTTTAAACCTATTCC
TTTGCCCTCGGACGAGTGCTGGG or anti-sense
oligo AGTTATGGTTTAAACCTATTCCTTTGC
CCTCGGACGAGTGCTGGGGCGTCGGTTTCCAC-
TATCGGCGAGAACTTCTAC (both carrying the Pme1
restriction site). The later anti-sense oligo is designed to
mutate the Sca1 restriction site present at the 3’ end of
the hygromycin resistant gene, without changing the
coded amino-acid (restriction enzyme Sca1 is used to
linearize the vector in order to make in vitro transcripts,
see below). The PCR products were cut with restriction
enzymes Asc1 and Pme1 and ligated to plasmid pFK
i389neoNS3-3’/NK5.1 that was cut with same restriction
enzymes to obtain pFK i389hygNS3-3’/NK5.1 and pFK
i389hygscalessNS3-3’/NK5.1. The resultant recombinant
plasmids were transformed into TOP10 competent bac-
teria (Invitrogen). Bacteria clones carrying the HCV-
hyg-Replicons were confirmed by restriction analysis
and sequencing. Plasmids pFK i389hygNS3-3’/NK5.1
(clones 2 and 3) were cut with restriction enzyme Spe 1
(generating a replicon with additional 4 nucleotides at
the 3’ end) and plasmids pFK i389hygscalessNS3-3’/
NK5.1 (clones 1 and 8) were cut with Sca1 (to obtain a
replicon with the authentic 3’ end sequence), and in
vitro transcribed using T7 Megascript kit (AMBION).
Generation of Huh7D cells
Huh7 cells grown in 12 well plates were transfected with
approximately 100 or 200 ng of HCV-neo-replicon using
as a facilitator 3 μl of lipofectamine (Invitrogen) in 200
μl of Optimem (Gibco). At 5 hours post transfection,
medium was replaced with DMEM containing 10% fetal
calf serum and antibiotics. Replicon harboring cells were
selected with G-418 (Roche) at a concentration of 250
μg/ml for 20 days. Single cell clones obtained by end-
point dilution were grown and tested by PCR and
Southern blot for the (lack of) incorporation of the Neo-
mycin resistance gene into the genome and by Northern
blot for the presence of the RNA transcript correspond-
i n gt ot h er e p l i c o n( n o ts h o w n ) .E x p r e s s i o no fH C V
protein was assessed by immunfluorscence using an
anti-NS5a antibody (not shown). Clone D, which had
high levels of HCV protein, harbored the HCV replicon,
and did not have the Neo gene integrated into the cellu-
lar genome, was selected for further analysis. Clone D
was “cured” from the replicon using a strategy similar as
the one previously described [6]. Briefly, Clone D cells
were passed four times at 7 or 8 day interval in absence
of G-418 and treated with human Interferon (Sigma
I2396) at a concentration of 100 IU/ml. After two
weeks, cells were tested for the absence of the HCV
replicon by RT-PCR and their susceptibility to G-418.
The expected PCR band was not detected, and cells
regained susceptibility to G-418 at a concentration of
250 μg/ml, which indicated that the Clone D cells were
cured from the HCV replicon, and were named Huh7D
cells.
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Huh7, Huh7D, and Huh7.5 cells grown in 12 well plates
were transfected with different amounts of HCV-neo- or
HCV-hyg replicons using as a facilitator 3 μl of lipofec-
tamine (Invitrogen) in 200 μl of Optimem (Gibco). At 5
hours post transfection, medium was replaced with
DMEM containing 10% fetal calf serum and antibiotics.
At 24 hours post transfection, medium was replaced
with same medium containing G-418 (Roche) at a con-
centration of 250 μg/ml (for HCV-neo-replicon trans-
fected cells) or hygromycin B (Roche) at a concentration
of 65 μg/ml (for HCV-hyg-replicon transfected cells).
To measure susceptibility to HCV replication, the HCV-
neo-replicon transfected cells were fixed 13 or 15 days
post transfection and stained with a solution of 50%
methanol and 10% acetic acid containing 0.6 g/L of
Comassie brilliant blue. The HCV-hyg-replicon trans-
fected cells were split in medium containing 65 μg/ml
hygromycin B, and colonies were stained with anti-HCV
specific antibody as described below.
Detection of HCV antigen by immunfluorscence (IF)
Cells transfected with HCV-hyg-replicon or infected
with HCV J6/JFH1 were fixed with methanol, blocked
with a solution containing 1% BSA and 0.2% non-fat
milk in 1 × PBS, treated with a 1:200 dilution in 0.05%
tween 20 in 1 × PBS of a serum from a persistently
infected chimpanzee that carried high levels of anti-
HCV antibodies [20] for 2 hours, washed with 1 × PBS,
stained with FITC-conjugated goat anti-human antibody
(KPL), washed, and observed in the microscope.
Infection of Huh7 cells with HCV J6/JFH1 and titration of
progeny virus
Huh7, Huh7D, and Huh7.5 cells grown in 6-well plates
were mock infected or infected with HCV-J6/JFH1 at an
moi of 0.01. At 6 hours post infection, cells were washed
three times with DMEM containing 10% FCS and split
into 12-well plates (for titration of total progeny virus)
and 96-well plates (for IF analysis, described above). At
0, 1, 3, 5, 7, and 10 dpi, the 12-well plates were frozen
at -70°C. For later time points, cells in one 12-well plate
were split and treated as described above. Total virus
from each time point was recovered by freezing and
thawing the cells 3 times. Viral titers were obtained in
Huh7.5 cells infected with 10-fold serial dilutions of the
cell extracts followed by detection of viral antigens by IF
analysis at three days post-infection as described above.
Amplification and sequencing of RIG-I mRNA
Total RNA was extracted from Huh7, Huh7D, and
Huh7.5 cells grown in T25 flasks using Trizol reagent as
recommended by the manufacturer (Invitrogen). cDNA
was synthesized using 4 μg of each RNA, SuperScript III
reverse transcriptase (Invitrogen), and random primers.
PCR amplification of RIG-I transcripts was performed
using RIG-I specific primers RIG-I 91+ (5’-
CTACCCGGCTTTAAAGCTAG-3 and RIG-I 3020- (5’-
CGATCCATGATTATACCCAC-3’). Nested-PCR was
performed using RIG-I-specific primers RIG-I 121+ (5’-
CCTGCGGGGAACGTAGCTAG-3’) and RIG-I 530-
(5’-AATGATATCGGTTGGGATAA-3’), RIG-I 421+ (5’-
CCATTGAAAGTTGGGATTTC-3’) and RIG-I 1410-
(5’-TGGCATCCCCAACACCAACC-3’), RIG-I 421+ and
RIG-I 2990-(5’-TCTTCTCCACTCAAAGTTAC-3’). The
Expand High Fidelity system (Roche) was used for PCR
amplifications as described by the manufacturer. PCR
products were run in agarose gels and purified using
gene-elute agarose gel columns (Sigma) and sequenced
(ABI-prism) using the above mentioned oligos and oli-
gos RIG-I 474- (5’-GTAATCTATACTCCTCCAAC-3’),
RIG-I 1331- (5’-AGATCAGAAACTTGGAGGAT-3’),
RIG-I 2281+ (5’-AGTGCAATCTTGTCATCCTT-3’),
and RIG-I 2360- (5’-TCTTGCTCTTCCTCTGCCTC-3’).
Additional file 1: Transfection of HCV-neo-replicon into Huh7,
Huh7D, and Huh7.5 cells. Coomassie staining of Huh7, Huh7D, and
Huh7.5 cells that were mock transfected or transfected with a replication-
defective HCV replicon, unrelated RNA, or with the indicated amounts of
HCV-neo-replicon, and selected for 15 days with G-418 at a
concentration of 250 μg/ml.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1743-422X-7-44-
S1.PDF]
Additional file 2: Alignment of nucleotide sequences of RIG-I mRNA
from Huh7, Huh7D, and Huh7.5 cells. Total RNA was extracted from
Huh7, Huh7D, and Huh7.5 cells and reverse transcribed using random
primers. RIG-I mRNA was amplified by PCR using RIG-I specific primers as
indicated in the Materials and Methods section. The alignment of the
three sequences was performed using the Clustal method.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1743-422X-7-44-
S2.PDF]
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